Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 7, 2009, Pages 726-729

  Ancel, David ^a   Amiot, Xavier ^a   Chaslin Ferbus, Dominique ^a   Hagege, Isabelle ^a   Garioud, Armand ^a   Girot, Robert ^a   Pol, Stanislas ^b   Grange, Jean Didier ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Hepatitis C virus; Pegylated interferon; Ribavirin; Sickle cell disease; Thalassaemia major

Indexed keywords

DEFEROXAMINE; HEMOGLOBIN; PARACETAMOL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LOW DRUG DOSE; MALE; MONOTHERAPY; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANEMIA, HEMOLYTIC; ANEMIA, SICKLE CELL; ANTIVIRAL AGENTS; BETA-THALASSEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; PILOT PROJECTS; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651043970     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283097699     Document Type: Article

References (32)

1. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J Clin Pathol 1990; 43:638-640. (Pubitemid 20228921)
2. Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica 1994; 79:353-355.
3. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343:388-390. (Pubitemid 24049557)
4. DeVault KR, Friedman LS, Westerberg S, Martin P, Hosein B, Ballas SK. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994; 18:206-209.
5. Bourliere M, Halfon P, Portal I. Treatment of chronic hepatitis C in special groups. Gastroenterol Clin Biol 2002; 26:B238-B247. (Pubitemid 34563481)
6. Hassan M, Hasan S, Giday S, Alamgir L, Banks A, Frederick W, Smoot D, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc 2003; 95:939-942. (Pubitemid 37296668)
7. Rebetol Product information Rev.8/01. Kenilworth, NJ: Schering corporation.
8. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30:956-961.
9. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
10. Mekeel KL, Langham MR Jr, Gonzalez-Peralta R, Fujita S, Hemming AW. Liver transplantation in children with sickle-cell disease. Liver Transpl 2007; 13:505-508. (Pubitemid 46605851)
11. Perronne V, Roberts-Harewood M, Bachir D, Roudot-Thoraval F, Delord JM, Thuret I, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J 2002; 3:56-60. (Pubitemid 34223917)
12. Swaim MW, Agarwal S, Rosse WF. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med 2000; 133:750-751. (Pubitemid 30822675)
13. Smoot DT. Response to 'Hepatitis C virus, sickle cell disease treatment options' - a February letter to the editor. J Natl Med Assoc 2004; 96:383.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432. (Pubitemid 28510876)
15. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652. (Pubitemid 37052151)
17. Mancuso A, Rigano P, Renda D, Di Salvo V, Pignatti CB, Guddo F, et al. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am J Hematol 2005; 78:158-159. (Pubitemid 40194114)
18. Syriopoulou V, Daikos GL, Kostaridou SL, Manolaki N, Nakopoulou L, Kattamis A, Kattamis C. Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica 2005; 90:129-131.
19. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br J Haematol 1993; 83:491-497. (Pubitemid 23080022)
20. Wonke B, Donohue SM, Hoffbrand AV, Scheuer PJ, Brown D, Dusheiko G. Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM). Bone Marrow Transplant 1993; 12 (Suppl 1):24-25.
21. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 1997; 90:2207-2212. (Pubitemid 27392704)
22. Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, Rapicetta M. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J 1997; 16:1049-1053. (Pubitemid 27494962)
23. Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis 1999; 18:709-715. (Pubitemid 29537449)
24. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Matsouka P, Spiliopoulou II, Barbatis C. Adult beta-thalassemic patients with chronic hepatitis C: long-term efficacy of alpha-IFN treatment. Eur J Intern Med 2000; 11:161-164. (Pubitemid 30347557)
25. Fontaine H. Hepatitis C in certain patient populations: children, patients with hemophilia and thalassemia, the hemodialyzed and kidney transplant recipients. Gastroenterol Clin Biol 2002; 26:B91-B104. (Pubitemid 34563462)
26. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, Wonke B. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997; 98:850-855. (Pubitemid 27421623)
27. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002; 117:755-758. (Pubitemid 34539259)
28. Demelia L, Civolani A, Murgia D, Murru A, Sorbello O, Rizzetto M. Tolerability of Peg interferon-alpha2b and ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency. J Hepatol 2007; 46:171-173. (Pubitemid 44827427)
29. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004. (Pubitemid 30169949)
30. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998; 123:1587-1592. (Pubitemid 28182042)
31. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005; 9:601-616. vi.
32. Itoh Y, Okanoue T. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients. J Gastroenterol 2004; 39:704-705.